DSC Equity Fund – Healthcare A|A

Reference Data

ISIN AT0000A1FNT0
Valor Number 28871817
Bloomberg Global ID
Fund Name DSC Equity Fund – Healthcare A|A
Fund Provider Dreyfus Söhne & Cie AG, Banquiers Aeschenvorstadt 16 | Postfach
4051 Basel
Schweiz
Phone: +41 61 286 66 66
Web: https://www.dreyfusbank.ch
Fund Provider Dreyfus Söhne & Cie AG, Banquiers
Representative in Switzerland Dreyfus Söhne & Cie AG, Banquiers
Basel
Distributor(s) Dreyfus Söhne & Cie AG, Banquiers
Basel
Asset Class Equities
EFC Category
Distribution Policy Distribution
Home Country Austria
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** N/A
Peculiarities

Fund Prices

Current Price * 203.26 CHF 03.11.2025
Previous Price * 203.22 CHF 31.10.2025
52 Week High * 237.48 CHF 04.03.2025
52 Week Low * 186.68 CHF 08.08.2025
NAV * 203.26 CHF 03.11.2025
Issue Price * 209.36 CHF 03.11.2025
Redemption Price * 203.26 CHF 03.11.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 38,219,823
Unit/Share Assets *** 36,600,033
Trading Information SIX

Performance

YTD Performance -9.21% 30.12.2024
03.11.2025
1 month -0.16% 03.10.2025
03.11.2025
3 months +8.03% 04.08.2025
03.11.2025
6 months -1.44% 05.05.2025
03.11.2025
1 year -12.80% 04.11.2024
03.11.2025
2 years -2.07% 03.11.2023
03.11.2025
3 years -13.07% 03.11.2022
03.11.2025
5 years -0.01% 03.11.2020
03.11.2025

Tax Data

Equity Participation Rate in % 96.46
Share of Total Fund Assets in %
Real Estate Rate in % 0.00
ADDI
ADDI Date

Top 10 Holdings ***

iShares MSCI Wld HlthCrSect AdvcdETF$Inc 9.64%
Johnson & Johnson 7.25%
Eli Lilly and Co 6.31%
Abbott Laboratories 4.61%
AbbVie Inc 4.57%
UnitedHealth Group Inc 3.97%
Merck & Co Inc 3.30%
AstraZeneca PLC 3.21%
Novartis AG Registered Shares 2.77%
Sanofi SA 2.69%
Last data update 30.09.2025

Cost / Risk

TER 1.49%
TER date 30.04.2025
Performance Fee ***
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 1.49%
SRRI ***
SRRI date *** 31.10.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)